A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis

Malignant cells --but not normal cells-- from patients with chronic lymphocytic leukemia (CLL) and other cancers, have high expression of the oncoembryonic protein ROR1 (Receptor tyrosine kinase-like Orphan Receptor 1). Activation of ROR1 on CLL cells induces proliferation and migration via activation of downstream targets, including RhoA, Rac1, and Akt. Cirmtuzumab (UC-961) is a first-in-class monoclonal antibody designed to inhibit ROR1 signaling.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Choi, Catriona Jamieson, George Widhopf, Jian Yu, Januario Castro, Reilly Kidwell, Hongying Li, Tiffany Juarez, Susette Gorak, Emily Pittman, Charlene Gutierrez, Laura Rassenti, Karen Messer, Charles Prussak, Thomas Kipps Source Type: research